Lupus

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Costedoat-Chalumeau, N
Right arrow Articles by Piette, J-C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Costedoat-Chalumeau, N
Right arrow Articles by Piette, J-C
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Lupus, Vol. 14, No. 9, 660-664 (2005)
DOI: 10.1191/0961203305lu2195oa

Anti-SSA/Ro and anti-SSB/La antibody-mediated congenital heart block

N Costedoat-Chalumeau

Service de Médecine Interne, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France, nathalie.costedoat{at}psl.ap-hop-paris.fr

S Georgin-Lavialle

Service de Médecine Interne, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France

Z Amoura

Service de Médecine Interne, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France

J-C Piette

Service de Médecine Interne, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France

When anti-SSA/Ro antibodies are present in sera of mothers with connective tissue diseases, the incidence of congenital heart block (CHB) has been reported to be 1-2% in live births. The risk of recurrence of CHB in a subsequent child remains limited to 10-16%. CHBs are usually complete but CHB of the first or second degree can also be observed. In some cases, CHB is associated with endocardial fibroelastosis. Late-onset cardiomyopathy may occur later in life in these children. The mortality of CHB, which is predominant in utero and in the first months of life, is an estimated 16-19%. A pacemaker is required in about 66% of cases. Curative treatment of CHB is based on fluorinated steroids (dexamethasone or betamethasone) that do cross the placenta in an active form. Guidelines are available but further studies are needed to optimize treatment.

Key Words: congenital heart block • connective tissue diseases • neonatal lupus syndrome • pregnancy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Ann. N. Y. Acad. Sci.Home page
S. ZAMPIERI, A. GHIRARDELLO, K. ROSSINI, L. IACCARINO, N. BASSI, F. ATZENI, P. SARZI-PUTTINI, and A. DORIA
Antigen Preparation for Immunological Studies in Systemic Autoimmune Diseases
Ann. N.Y. Acad. Sci., August 1, 2007; 1109(1): 193 - 202.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
A Brucato, M G Astori, R Cimaz, P Villa, M Li Destri, L Chimini, R Vaccari, M Muscara, M Motta, A Tincani, et al.
Normal neuropsychological development in children with congenital complete heart block who may or may not be exposed to high-dose dexamethasone in utero
Ann Rheum Dis, November 1, 2006; 65(11): 1422 - 1426.
[Abstract] [Full Text] [PDF]